XL413

XL413 is a potent, selective and ATP competitive inhibitor of Cdc7, with an IC50 of 3.4 nM, and also shows potent effect with IC50s of 215, 42 nM on CK2, PIM1, respectively, and an EC50 of 118 nM on pMCM.

Product Specifications

CAS Number

[1169558-38-6]

Product Name Alternative

BMS-863233

UNSPSC

12352005

Hazard Statement

H302

Target

CDK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/xl413.html

Purity

99.76

Solubility

10 mM in DMSO

Smiles

ClC1=CC=C2C(C(N=C([C@@H]3CCCN3)NC4=O)=C4O2)=C1

Molecular Formula

C14H12ClN3O2

Molecular Weight

289.72

Precautions

H302

References & Citations

[1]Koltun ES, et al. Discovery of XL413, a potent and selective CDC7 inhibitor. Bioorg Med Chem Lett. 2012 Jun 1;22 (11) :3727-31.|[2]Sasi NK, et al. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds. PLoS One. 2014 Nov 20;9 (11) :e113300.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

CDC

Citation 01

MedComm (2020) . 2025 May 15;6 (6) :e70150.|Am J Physiol Lung Cell Mol Physiol. 2018 Sep 1;315 (3) :L360-L370.|Harvard Medical School LINCS LIBRARY|Science. 2017 Dec 1;358 (6367) :eaan4368.|Sens Actuators B Chem. 15 May 2022, 131618.|University of Washington. 2025.